Fig. 3
From: Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Cell proliferation using alamarblue® assay (a) and Vybrant MTT® assay (b) of prostate-induced bone metastasis cells treated with vehicle (PBS1x) or zol 1 µM, 3 µM and 10 µM for 7 days in 1% serum conditions. The histograms in (a) and (b) represent the ratio of drug-treated cells divided by vehicle-treated cells (PBS1x). c representative photos of Live/Dead assay carried out on LAPC4 following vehicle or zol treatment at different concentrations. Live cells are in green and dead cells are designated in red arrow heads. d Percentage of viable cells [number of live cells/(number of live cells + number of dead cells) * 100] and e ratio of live cells or dead cells in vehicle or zol-treated conditions, Results are mean ± SD of three independent experiments, p < 0.05. Scale bar 100 µm